TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Early Supported Discharge After Stroke in Bergen. An RCT Looking at the Collaboration Between Hospital Service and Primary Health Care.
Brief Summary: The main purpose of this study is to evaluate the benefit of early supported discharge (ESD) in rehabilitation of stroke patients in two different outpatient modalities.

In a collaborating study, changes in physical function as well as the patients' own perception of physical function, pain and fatigue will be studied. In further collaborating studies, health economics and organizational issues will also be evaluated.


Options:
A: Arm Label: Hospital Inpatient Rehabilitation (HI); Type: ACTIVE_COMPARATOR; Interventions: Other: Hospital Inpatient Rehabilitation | Arm Label: Hybrid Home Programme (HO); Type: ACTIVE_COMPARATOR; Interventions: Other: Hybrid Home Programme (HO) | Intervention Type: OTHER; Name: Hospital Inpatient Rehabilitation; Assigned to Arm(s): Hospital Inpatient Rehabilitation (HI) | Intervention Type: OTHER; Name: Hybrid Home Programme (HO); Assigned to Arm(s): Hybrid Home Programme (HO)
B: Arm Label: Day unit rehabilitation; Type: ACTIVE_COMPARATOR; Interventions: Other: Early supported discharge with day unit rehabilitation | Arm Label: Home rehabilitation; Type: ACTIVE_COMPARATOR; Interventions: Other: Early supported discharge with home rehabilitation | Arm Label: Treatment as usual; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Early supported discharge with day unit rehabilitation; Assigned to Arm(s): Day unit rehabilitation | Intervention Type: OTHER; Name: Early supported discharge with home rehabilitation; Assigned to Arm(s): Home rehabilitation
C: Arm Label: Active; Type: EXPERIMENTAL; Interventions: Other: Very early supported discharge (VESD) | Arm Label: Control; Type: OTHER; Interventions: Other: Ordinary rehabilitation | Intervention Type: OTHER; Name: Very early supported discharge (VESD); Assigned to Arm(s): Active | Intervention Type: OTHER; Name: Ordinary rehabilitation; Assigned to Arm(s): Control
D: Arm Label: Psychoeducative intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Psychoeducative intervention | Arm Label: Usual care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Psychoeducative intervention; Assigned to Arm(s): Psychoeducative intervention

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A 24-Week, Double-Blind, Placebo-Controlled, Parallel-Group, Fixed-Dosage Study to Evaluate the Efficacy and Safety of Armodafinil (150, 200, and 250 mg/ Day) as Adjunctive Therapy in Adults With Schizophrenia
Brief Summary: The primary objective of the study is to evaluate whether armodafinil treatment is more effective than placebo as adjunctive therapy to antipsychotic medication in alleviating the negative symptoms of schizophrenia


Options:
A: Arm Label: 150 mg/day armodafinil; Type: ACTIVE_COMPARATOR; Interventions: Drug: armodafinil | Arm Label: 200 mg/day armodafinil; Type: ACTIVE_COMPARATOR; Interventions: Drug: armodafinil | Arm Label: 250 mg/day armodafinil; Type: ACTIVE_COMPARATOR; Interventions: Drug: armodafinil | Arm Label: Matching Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: armodafinil; Assigned to Arm(s): 150 mg/day armodafinil | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): Matching Placebo | Intervention Type: DRUG; Name: armodafinil; Assigned to Arm(s): 200 mg/day armodafinil | Intervention Type: DRUG; Name: armodafinil; Assigned to Arm(s): 250 mg/day armodafinil
B: Arm Label: 50 mg/day armodafinil; Type: ACTIVE_COMPARATOR; Interventions: Drug: armodafinil | Arm Label: 100 mg/day armodafinil; Type: ACTIVE_COMPARATOR; Interventions: Drug: armodafinil | Arm Label: 200 mg/day armodafinil; Type: ACTIVE_COMPARATOR; Interventions: Drug: armodafinil | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: armodafinil; Assigned to Arm(s): 50 mg/day armodafinil | Intervention Type: DRUG; Name: armodafinil; Assigned to Arm(s): 100 mg/day armodafinil | Intervention Type: DRUG; Name: armodafinil; Assigned to Arm(s): 200 mg/day armodafinil | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): Placebo
C: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: armodafinil (Nuvigil) | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: armodafinil (Nuvigil); Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): 2
D: Arm Label: modafinil; Type: EXPERIMENTAL; Interventions: Drug: modafinil | Arm Label: placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: modafinil; Assigned to Arm(s): modafinil | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): placebo

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Controlled Trial in Women With Recurrent Miscarriage of G-CSF Versus Placebo
Brief Summary: In order to investigate the effectiveness of G-CSF in preventing embryo demise, the investigators administered this cytokine to women with recurrent miscarriage in a randomized controlled study compared to women treated with placebo. Sixty eight women with unexplained primary recurrent miscarriage, all of them with at least four consecutive abortions and negative for all clinical investigations were selected for this study. Patients were randomly treated with G-CSF, starting on the 6th day after ovulation, or with placebo.


Options:
A: Arm Label: enoxaparin fixed; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: enoxaparin adjusted; Type: EXPERIMENTAL; Interventions: Drug: enoxaparin | Intervention Type: DRUG; Name: enoxaparin; Assigned to Arm(s): enoxaparin adjusted
B: Arm Label: Standard of Care Arm; Type: ACTIVE_COMPARATOR; Interventions: Drug: Low-molecular-weight heparin | Arm Label: Experimental Arm; Type: EXPERIMENTAL; Interventions: Drug: Aspirin 81 mg | Intervention Type: DRUG; Name: Aspirin 81 mg; Assigned to Arm(s): Experimental Arm | Intervention Type: DRUG; Name: Low-molecular-weight heparin; Assigned to Arm(s): Standard of Care Arm
C: Arm Label: Granulocyte colony stimulating factor; Type: EXPERIMENTAL; Interventions: Drug: G-CSF | Arm Label: placebo (saline solution); Type: PLACEBO_COMPARATOR; Interventions: Drug: saline solution | Intervention Type: DRUG; Name: G-CSF; Assigned to Arm(s): Granulocyte colony stimulating factor | Intervention Type: DRUG; Name: saline solution; Assigned to Arm(s): placebo (saline solution)
D: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Biological: Gamimune N or Gamunex 10% | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Other: normal saline | Intervention Type: BIOLOGICAL; Name: Gamimune N or Gamunex 10%; Assigned to Arm(s): 1 | Intervention Type: OTHER; Name: normal saline; Assigned to Arm(s): 2

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase III Trial Assessing the Pharmacodynamic Effect and the Tolerability of Grazax Treatment Initiated in the Grass Pollen Season in Subjects With Seasonal Grass Pollen Induced Rhinoconjunctivitis
Brief Summary: The study assess the pharmacodynamic effect and the tolerability of Grazax treatment initiated in the grass pollen season in subjects with seasonal grass pollen induced rhinoconjunctivitis


Options:
A: Intervention Type: DRUG; Name: ALK HDM tablet; Assigned to Arm(s): N/A
B: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Grazax | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: Grazax; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): 2
C: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: MK-8237 6 Developmental Units (DU); Type: EXPERIMENTAL; Interventions: Drug: MK-8237 6 DU | Arm Label: MK-8237 12 DU; Type: EXPERIMENTAL; Interventions: Drug: MK-8237 12 DU | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: MK-8237 6 DU; Assigned to Arm(s): MK-8237 6 Developmental Units (DU) | Intervention Type: DRUG; Name: MK-8237 12 DU; Assigned to Arm(s): MK-8237 12 DU
D: Arm Label: Oral mucosal immunoprophylaxis (OMIP); Type: EXPERIMENTAL; Interventions: Biological: Oral mucosal immunoprophylaxis (OMIP) | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Biological: Placebo | Intervention Type: BIOLOGICAL; Name: Oral mucosal immunoprophylaxis (OMIP); Assigned to Arm(s): Oral mucosal immunoprophylaxis (OMIP) | Intervention Type: BIOLOGICAL; Name: Placebo; Assigned to Arm(s): Placebo

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase III Trial Assessing the Pharmacodynamic Effect and the Tolerability of Grazax Treatment Initiated in the Grass Pollen Season in Subjects With Seasonal Grass Pollen Induced Rhinoconjunctivitis
Brief Summary: The study assess the pharmacodynamic effect and the tolerability of Grazax treatment initiated in the grass pollen season in subjects with seasonal grass pollen induced rhinoconjunctivitis


Options:
A: Arm Label: 300 IR; Type: EXPERIMENTAL; Interventions: Drug: 300 IR | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: 300 IR; Assigned to Arm(s): 300 IR | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
B: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: MK-8237 6 Developmental Units (DU); Type: EXPERIMENTAL; Interventions: Drug: MK-8237 6 DU | Arm Label: MK-8237 12 DU; Type: EXPERIMENTAL; Interventions: Drug: MK-8237 12 DU | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: MK-8237 6 DU; Assigned to Arm(s): MK-8237 6 Developmental Units (DU) | Intervention Type: DRUG; Name: MK-8237 12 DU; Assigned to Arm(s): MK-8237 12 DU
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Grazax | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Grazax | Intervention Type: DRUG; Name: Grazax; Assigned to Arm(s): 1, 2
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Grazax | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: Grazax; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): 2

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase 2B, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging, Efficacy and Safety Study of Apremilast (CC-10004) in Subjects With Moderate-to-Severe Plaque-Type Psoriasis (Core Study)
Brief Summary: The purpose of this study was to test if the drug apremilast was safe, if it helped improve psoriasis, and how well the participants tolerated it.


Options:
A: Intervention Type: DRUG; Name: etanercept; Assigned to Arm(s): N/A
B: Arm Label: Arm 1; Type: EXPERIMENTAL; Interventions: Drug: BI 655066 | Arm Label: Arm 2; Type: EXPERIMENTAL; Interventions: Drug: BI 655066 | Arm Label: Arm 3; Type: EXPERIMENTAL; Interventions: Drug: BI 655066 | Arm Label: Arm 4; Type: ACTIVE_COMPARATOR; Interventions: Drug: Ustekinumab | Intervention Type: DRUG; Name: BI 655066; Assigned to Arm(s): Arm 2 | Intervention Type: DRUG; Name: BI 655066; Assigned to Arm(s): Arm 3 | Intervention Type: DRUG; Name: Ustekinumab; Assigned to Arm(s): Arm 4 | Intervention Type: DRUG; Name: BI 655066; Assigned to Arm(s): Arm 1
C: Arm Label: BMS-986165; Type: EXPERIMENTAL; Interventions: Drug: BMS-986165 | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Arm Label: Apremilast; Type: ACTIVE_COMPARATOR; Interventions: Drug: Apremilast | Intervention Type: DRUG; Name: BMS-986165; Assigned to Arm(s): BMS-986165 | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: Apremilast; Assigned to Arm(s): Apremilast
D: Arm Label: Apremilast 10mg; Type: EXPERIMENTAL; Interventions: Drug: Apremilast 10mg | Arm Label: Apremilast 20mg; Type: EXPERIMENTAL; Interventions: Drug: Apremilast 20mg | Arm Label: Apremilast 30 mg; Type: EXPERIMENTAL; Interventions: Drug: Apremilast 30 mg | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Placebo/Apremilast 20 mg; Type: EXPERIMENTAL; Interventions: Drug: Apremilast 20mg | Arm Label: Placebo/Apremilast 30mg; Type: EXPERIMENTAL; Interventions: Drug: Apremilast 30mg | Intervention Type: DRUG; Name: Apremilast 10mg; Assigned to Arm(s): Apremilast 10mg | Intervention Type: DRUG; Name: Apremilast 20mg; Assigned to Arm(s): Apremilast 20mg | Intervention Type: DRUG; Name: Apremilast 30 mg; Assigned to Arm(s): Apremilast 30 mg | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: Apremilast 30mg; Assigned to Arm(s): Placebo/Apremilast 30mg | Intervention Type: DRUG; Name: Apremilast 20mg; Assigned to Arm(s): Placebo/Apremilast 20 mg

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase 2B, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging, Efficacy and Safety Study of Apremilast (CC-10004) in Subjects With Moderate-to-Severe Plaque-Type Psoriasis (Core Study)
Brief Summary: The purpose of this study was to test if the drug apremilast was safe, if it helped improve psoriasis, and how well the participants tolerated it.


Options:
A: Arm Label: Placebo (Part A); Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo for risankizumab, Drug: placebo for ustekinumab | Arm Label: Ustekinumab (Part A); Type: ACTIVE_COMPARATOR; Interventions: Drug: placebo for risankizumab, Drug: ustekinumab | Arm Label: Risankizumab (Part A); Type: EXPERIMENTAL; Interventions: Drug: risankizumab, Drug: placebo for ustekinumab | Intervention Type: DRUG; Name: risankizumab; Assigned to Arm(s): Risankizumab (Part A) | Intervention Type: DRUG; Name: placebo for risankizumab; Assigned to Arm(s): Placebo (Part A), Ustekinumab (Part A) | Intervention Type: DRUG; Name: ustekinumab; Assigned to Arm(s): Ustekinumab (Part A) | Intervention Type: DRUG; Name: placebo for ustekinumab; Assigned to Arm(s): Placebo (Part A), Risankizumab (Part A)
B: Arm Label: Ixekizumab; Type: EXPERIMENTAL; Interventions: Drug: Ixekizumab | Arm Label: Fumaric Acid Esters; Type: ACTIVE_COMPARATOR; Interventions: Drug: Fumaric Acid Esters, Drug: Ixekizumab | Arm Label: Methotrexate; Type: ACTIVE_COMPARATOR; Interventions: Drug: Methotrexate, Drug: Ixekizumab | Intervention Type: DRUG; Name: Fumaric Acid Esters; Assigned to Arm(s): Fumaric Acid Esters | Intervention Type: DRUG; Name: Methotrexate; Assigned to Arm(s): Methotrexate | Intervention Type: DRUG; Name: Ixekizumab; Assigned to Arm(s): Fumaric Acid Esters, Ixekizumab, Methotrexate
C: Intervention Type: DRUG; Name: Etanercept; Assigned to Arm(s): N/A
D: Arm Label: Apremilast 10mg; Type: EXPERIMENTAL; Interventions: Drug: Apremilast 10mg | Arm Label: Apremilast 20mg; Type: EXPERIMENTAL; Interventions: Drug: Apremilast 20mg | Arm Label: Apremilast 30 mg; Type: EXPERIMENTAL; Interventions: Drug: Apremilast 30 mg | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Placebo/Apremilast 20 mg; Type: EXPERIMENTAL; Interventions: Drug: Apremilast 20mg | Arm Label: Placebo/Apremilast 30mg; Type: EXPERIMENTAL; Interventions: Drug: Apremilast 30mg | Intervention Type: DRUG; Name: Apremilast 10mg; Assigned to Arm(s): Apremilast 10mg | Intervention Type: DRUG; Name: Apremilast 20mg; Assigned to Arm(s): Apremilast 20mg | Intervention Type: DRUG; Name: Apremilast 30 mg; Assigned to Arm(s): Apremilast 30 mg | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: Apremilast 30mg; Assigned to Arm(s): Placebo/Apremilast 30mg | Intervention Type: DRUG; Name: Apremilast 20mg; Assigned to Arm(s): Placebo/Apremilast 20 mg

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Neuronal Nicotinic Receptor Modulation in the Treatment of Autism: A Pilot Trial of Mecamylamine
Brief Summary: The purpose of this study is to examine the safety and efficacy of mecamylamine for the core symptoms of autism.


Options:
A: Arm Label: Active Mecamylamine; Type: EXPERIMENTAL; Interventions: Drug: mecamylamine | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: mecamylamine; Assigned to Arm(s): Active Mecamylamine | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): Placebo
B: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Balovaptan (RO5285119) 10 mg/d equivalent; Type: EXPERIMENTAL; Interventions: Drug: RO5285119 | Arm Label: Balovaptan (RO5285119) 4 mg/d equivalent; Type: EXPERIMENTAL; Interventions: Drug: RO5285119 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: RO5285119; Assigned to Arm(s): Balovaptan (RO5285119) 10 mg/d equivalent, Balovaptan (RO5285119) 4 mg/d equivalent
C: Arm Label: Lurasidone 20 mg; Type: EXPERIMENTAL; Interventions: Drug: Lurasidone 20 mg daily | Arm Label: Lurasidone 60 mg; Type: EXPERIMENTAL; Interventions: Drug: Lurasidone | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Lurasidone 20 mg daily; Assigned to Arm(s): Lurasidone 20 mg | Intervention Type: DRUG; Name: Lurasidone; Assigned to Arm(s): Lurasidone 60 mg | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: Social Skills Focused CBT; Type: EXPERIMENTAL; Interventions: Behavioral: Social Skills focused CBT | Arm Label: Stress Management/Relaxation Training; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Stress management/relaxation training | Arm Label: Oxytocin; Type: EXPERIMENTAL; Interventions: Drug: Oxytocin | Arm Label: placebo drug; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo drug | Intervention Type: DRUG; Name: Oxytocin; Assigned to Arm(s): Oxytocin | Intervention Type: BEHAVIORAL; Name: Social Skills focused CBT; Assigned to Arm(s): Social Skills Focused CBT | Intervention Type: BEHAVIORAL; Name: Stress management/relaxation training; Assigned to Arm(s): Stress Management/Relaxation Training | Intervention Type: DRUG; Name: placebo drug; Assigned to Arm(s): placebo drug

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Neuronal Nicotinic Receptor Modulation in the Treatment of Autism: A Pilot Trial of Mecamylamine
Brief Summary: The purpose of this study is to examine the safety and efficacy of mecamylamine for the core symptoms of autism.


Options:
A: Arm Label: Active Mecamylamine; Type: EXPERIMENTAL; Interventions: Drug: mecamylamine | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: mecamylamine; Assigned to Arm(s): Active Mecamylamine | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): Placebo
B: Arm Label: IGF-1; Type: EXPERIMENTAL; Interventions: Drug: IGF-1 | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo/saline | Intervention Type: DRUG; Name: IGF-1; Assigned to Arm(s): IGF-1 | Intervention Type: DRUG; Name: Placebo/saline; Assigned to Arm(s): Placebo
C: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: atomoxetine, Behavioral: Parent Management Training | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: atomoxetine | Arm Label: 3; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo, Behavioral: Parent Management Training | Arm Label: 4; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: atomoxetine; Assigned to Arm(s): 1, 2 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 3, 4 | Intervention Type: BEHAVIORAL; Name: Parent Management Training; Assigned to Arm(s): 1, 3
D: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: RG7314; Type: EXPERIMENTAL; Interventions: Drug: RG7314 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: RG7314; Assigned to Arm(s): RG7314

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Neuronal Nicotinic Receptor Modulation in the Treatment of Autism: A Pilot Trial of Mecamylamine
Brief Summary: The purpose of this study is to examine the safety and efficacy of mecamylamine for the core symptoms of autism.


Options:
A: Arm Label: DB Placebo Nasal Spray; Type: PLACEBO_COMPARATOR; Interventions: Drug: Double blind phase Placebo Nasal Spray | Arm Label: DB Oxytocin Nasal Spray; Type: ACTIVE_COMPARATOR; Interventions: Drug: double Blind Oxytocin Nasal Spray | Arm Label: open label intranasal oxytocin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Open Label intranasal oxytocin | Intervention Type: DRUG; Name: Double blind phase Placebo Nasal Spray; Assigned to Arm(s): DB Placebo Nasal Spray | Intervention Type: DRUG; Name: double Blind Oxytocin Nasal Spray; Assigned to Arm(s): DB Oxytocin Nasal Spray | Intervention Type: DRUG; Name: Open Label intranasal oxytocin; Assigned to Arm(s): open label intranasal oxytocin
B: Arm Label: Oxytocin; Type: EXPERIMENTAL; Interventions: Drug: Intranasal Oxytocin | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Intranasal Oxytocin; Assigned to Arm(s): Oxytocin | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: Atomoxetine; Type: EXPERIMENTAL; Interventions: Drug: Atomoxetine | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Atomoxetine; Assigned to Arm(s): Atomoxetine | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: Active Mecamylamine; Type: EXPERIMENTAL; Interventions: Drug: mecamylamine | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: mecamylamine; Assigned to Arm(s): Active Mecamylamine | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): Placebo

Answer: D